Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec-Preliminary Results

• Published in: Children (Basel) 2023-06, Vol.10 (6), p.998
• Main Authors: Soini, Venla, Schreiber, Gudrun, Wilken, Bernd, Hell, Anna Kathrin
• Format: Article
• Language: English
• Subjects: Age; Atrophy; Care and treatment; Drug therapy; Gene therapy; Genes; kyphosis; Medical prognosis; Medical records; Mutation; Neuromuscular diseases; Patients; Scoliosis; Spinal muscular atrophy; Statistical significance; Ventilation
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children10060998

Spinal muscular atrophy (SMA) is a rare genetic disorder, with the most common form being 5q SMA. Survival of children with severe SMA is poor, yet major advances have been made in recent years in pharmaceutical treatment, such as gene-therapy, which has improved patient survival. Therefore, clinical problems, such as the development of spinal deformities in these genetically treated SMA children represent an unknown challenge in clinical work. In a retrospective case series, the development of spinal deformities was analyzed in 16 SMA children (9 male, 7 female) treated with onasemnogene abeparvovec in two institutions during the years 2020 to 2022. Ten out of sixteen patients had a significant kyphosis, and nine out of sixteen patients had significant scoliosis, with the mean curvature angles of 24 ± 27° for scoliosis, and 69 ± 15° for kyphosis. Based on these preliminary data, it can be assumed that early-onset kyphosis presents a clinical challenge in gene-therapy-treated SMA children. Larger datasets with longer follow-up times need to be collected in order to verify these preliminary observations.